Highlights from the first day included updates from Exact Sciences about its plans for new tests slated for this year and ...

The report also indicates that while PAMA has cut spending on routine tests, overall lab spending has risen as genetic testing continues to grow.

The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.

The recent clearance and a previous clearance together allow the use of Paige's FullFocus digital pathology image viewing software with scanners by Philips, Leica, and Hamamatsu.

The company said it expects Q4 2024 revenues of roughly $34.9 million, up from $31.5 million in Q4 2023 and above the consensus Wall Street estimate of $34.4 million.

NEW YORK – Pathology software developer Aiosyn said recently that it has gained CE marking for an algorithm that is used for mitotic figure counting in breast cancer diagnostics. The Nijmegen, ...

Last week, readers were most interested in a story about the progress made by test developers toward commercializing rapid tests for sepsis.

The reagents are meant for measuring aCL and aβ2GP1 antibody levels in human serum to aid the diagnosis of primary and secondary APS.

Following OraSure's November 2024 lawsuit accusing NowDx of misappropriating trade secrets, NowDx has countersued OraSure over similar allegations.

Rounding out the other four largest financing rounds in 2024 are proteomics company Alamar Biosciences' $128 million Series C ...

Numerous firms reported preliminary revenues along with other business updates on Sunday and Monday ahead of the annual JP Morgan Healthcare Conference.

The company received conditional approval from New York state for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays.